Tricosilk Max Solution is a combination of two hair growth promoters: Aminexil and MINOXIDIL TOPICAL. Aminexil suppresses an enzyme which causes buildup of a protein (collagen) around the hair follicles, leading to hair loss. MINOXIDIL TOPICAL is a vasodilator, meaning it widens the blood vessels and provides better blood flow to the hair follicles. This prevents hair loss and stimulates re-growth resulting in longer, thicker and increased numbers of hair.
Tricosilk Max Solution may be unsafe to use during pregnancy. Animal studies have shown adverse effects on the foetus, however, there are limited human studies. The benefits from use in pregnant women may be acceptable despite the risk. Please consult your doctor.
Tricosilk Max Solution is probably safe to use during lactation.
Limited human data suggests that the drug does not represent a significant risk to the baby.
Tricosilk Max Solution may make you feel dizzy, sleepy, tired, or decrease alertness. If this happens, do not drive.
Tricosilk Max Solution is probably safe to use in patients with kidney disease. Limited data available suggests that dose adjustment of Tricosilk Max Solution may not be needed in these patients. Please consult your doctor.
Tricosilk Max Solution is probably safe to use in patients with liver disease. Limited data available suggests that dose adjustment of Tricosilk Max Solution may not be needed in these patients. Please consult your doctor.
What were the side-effects while using Tricosilk Max Solution?
No Side Effect
How do you take Tricosilk Solution?
With or without food
How much was the improvement?
Please rate Tricosilk Max Solution on price
What are you using Tricosilk Solution for?
Survey Participants: 33
“The following are the results of on-going survey on 1mg.com for Tricosilk Max Solution. These results only indicate the perceptions of the website users. Please base your medical decisions only on the advice of a doctor or a registered medical professional.”
Information last updated by Dr. Varun Gupta, MD Pharmacology on 4th May 2017.